Serum immunoreactive interleukin‐6 and C‐reactive protein levels in patients with multiple myeloma at diagnosis

Summary Serum bioactive but not immunoreactive interleukin‐6 (IL‐6), and serum C‐reactive protein (CRP), have been reported to be of prognostic significance in multiple myeloma (MM). We measured serum immunoreactive IL‐6 by a sensitive enzyme‐linked immunosorbent assay in 30 MM patients at diagnosis. In 30% of the patients serum immuno‐reactive IL‐6 exceeded the upper reference limit. The concentrations of CRP and IL‐6 showed a linear association. Logarithmically transformed IL‐6, CRP and β2‐microglobulin were significant variables by univariate survival analysis: by multivariate analysis CRP was a slightly stronger prognostic factor than IL‐6 and the only one of independent prognostic significance.

[1]  P. Gobbi,et al.  Acute phase proteins and prognosis in multiple myeloma , 1993, British journal of haematology.

[2]  B. Klein,et al.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. , 1992, Blood.

[3]  E. Solary,et al.  Radioimmunoassay for the measurement of serum IL‐6 and its correlation with tumour cell mass parameters in multiple myeloma , 1992, American journal of hematology.

[4]  H. Ludwig,et al.  Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments] , 1991 .

[5]  R. Giacomelli,et al.  Cytokine production in patients with monoclonal gammapathies. , 1991, Journal of clinical & laboratory immunology.

[6]  H. Ludwig,et al.  Interleukin-6 is a prognostic factor in multiple myeloma. , 1991, Blood.

[7]  D. Joshua,et al.  The use of a commercially available immunoassay to determine the level of interleukin-6 in the serum of patients with myeloma. , 1991, Leukemia & lymphoma.

[8]  P. Heinrich,et al.  Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6 , 1990, Hepatology.

[9]  M. Jourdan,et al.  Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. , 1990, European cytokine network.

[10]  M. Jourdan,et al.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. , 1989, The Journal of clinical investigation.

[11]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.